Table 3.
Major phase 3 trials involving targeted immunotherapeutic agents in the advanced/metastatic gastric cancer setting
| Trials | No. of patients | Treatment arms | HR for death (P value) | Primary endpoint comparison (in months) |
|---|---|---|---|---|
| Advanced gastric cancer – first line | ||||
| Bang et al. 26 (ToGA)a | 584 | CX/CF + Trastuzumab versus CX/CF | 0.74 (0.0046) | OS: 13.8 versus 11.1 |
| Advanced gastric cancer – Second line | ||||
| Fuchs et al. 32 (REGARD) | 355 | Ramucirumab + BSC versus BSC | 0.776 (0.0473) | OS: 5.2 versus 3.8 |
| Wilke et al. 33 (RAINBOW) | 665 | Paclitaxel + Ramucirumab versus Paclitaxel | 0.81 (0.017) | OS: 9.6 versus 7.4 |
| Advanced gastric cancer – third line | ||||
| Li et al. 34 (Apatinib) | 271 | Apatinib + BSC versus BSC | 0.71 (0.0149) | OS: 6.5 versus 4.7PFS: 2.6 versus 1.8 |
| Kang et al. 46 (ONO‐4538‐12, ATTRACTION‐2) | 493 | Nivolumab versus Placebo | 0.63 (<0.0001) | OS: 5.26 versus 4.14 |
HR, Hazard ratio; OS, Overall survival; CX, Cisplatin and Capecitabine; CF, Cisplatin and 5‐FU; PFS, Progression‐free survival; BSC, Best supportive care.
a
Hazard ratio reduced to 0.8 on follow‐up analysis.